Mobidiag Secures €25M Loan to Build Test Menu

May 14, 2019

|

NEW YORK (GenomeWeb) – Mobidiag announced today it has secured a four-year growth capital loan for €25 million ($28 million) from the European Investment Bank which will be used to expand the assay menu on its automated molecular diagnostic instruments.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Keep Them or Not?

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

Dunno Whose It Is

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

Knowing Risk From a Young Age

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

Science Translational Medicine Paper Finds Drug Combo Boosts KRAS Inhibitor Efficacy in Lung Cancer

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.

Featured White Papers

Sample Normalization with RNAGEM

RNAGEM - mRNA Profiles as Close to Biological Reality as Possible

Cell-Based Therapies – Be on the Safe Side

Poster: Next Generation Cellular Therapeutic Technologies — Rapid Detection of Bacterial Contamination

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Menu